Chemistry, Probes, & Molecular Therapy (CPMT): "Lumi804, a novel bifunctional chelator for targeted PET imaging and radiotherapy"
Date
Password: 593478
3246 America/Los_Angeles public
Type
Time Duration
Password: 593478
Speakers
Director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging (CMFI)
Henry VanBrocklin, PhD, is a Professor in Residence, Director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging (CMFI) at the University of California, San Francisco China Basin, and he is a Joint Faculty Scientist at the Lawrence Berkeley National Laboratory. Dr. VanBrocklin obtained his PhD in Radiopharmaceutical Chemistry from Washington University, St. Louis in 1990, and he completed a two-year postdoctoral program at the University of Illinois, Urbana in 1992. He maintains an active radiotracer research program in addition to providing tracers for collaborative basic science and translational clinical research. His research interests include short-lived radioisotope production to the creation of fluorine-18 and carcbon-11 labeling chemistry strategies for new radiotracer preparations and applications.
Dr. VanBrocklin is one of the core faculty for the Master's in Biomedical Imaging (MSBI) program and a member of the MSBI executive committee.
Dr. VanBrocklin was awarded the Alexander Hollaender Distinguished Postdoctoral Fellowship from the U.S. Department of Energy for developing positron-labeled estrogens, progestins, and androgens for tumor imaging. He has 70 published research articles.
Expertise:
Radiopharmaceutical
Specialty:
Short-lived radioisotope production to the creation of fluorine-18 and carbon-11 labeling chemistry strategies for new radiotracer preparations and applications, development of positron-labeled estrogens, progestin’s, androgens for tumor imaging
Professional Interests:
Developing radiopharmaceutical probes for PET and SPECT imaging applications including tracers for blood flow measurement, receptor-targeted tracers for prostate, pancreatic and breast cancer, and neurological imaging agents for neuroinflammation and excititory amino acid transport.
Dr. Magda has a B.S. degree in Chemistry and completed his Ph.D. degree at the University of Texas with Professor Jonathan Sessler in 1990. Following a postdoctoral appointment at the California Institute of Technology he joined Pharmacyclics in 1993, a pharmaceutical company based in Sunnyvale, CA. From 1998 to 2009 he was Director of Exploratory Research at Pharmacyclics. Dr. Magda’s expertise in the laboratory ranges most aspects of preclinical chemistry and biology, with emphasis on developing metal complexes for use in medicine. Among other professional societies, he is a member of the Radiation Research Society and American Association for Cancer Research. Dr. Magda manages much of the laboratory work associated with our on-going projects and currently serves as Co-Chair of Lumiphore’s Scientific Advisory Board.
Dr. Tatum received his B.S. in Chemistry and B.S. in Biochemistry from Virginia Tech in 2009, where he worked for Prof. Gordon Yee on molecule-based magnetism. He completed his Ph.D. in Chemistry at UC Berkeley with Prof. Ken Raymond in 2014, and he has worked for Lumiphore Inc. since that time. Dr. Tatum brings his expertise in Eu(III) luminescence to Lumiphore, culminating in the design and synthesis of a new class of macrocyclic bifunctional chelators having unprecedented stability with radiometal ions of interest (e.g. Lu-177, Zr-89, and Th-227). These new materials also form very bright and stable Eu(III) photoluminescent dyes, making Lumiphore the proprietary owner of best-in-class lanthanide dyes for both Eu(III) and Tb(III).